Saturday, 31 October 2026European Markets

HEINEKEN HOLDING And HEINEKEN Have A High Dividend Yield And Return On Equity In The Beverages—Brewers Industry.

Loading stream...

(VIANEWS) - HEINEKEN HOLDING (HEIO.AS) is among this list of stock assets with the highest dividend rate and return on equity on the Beverages—Brewers industry.

Financial Asset Price Forward Dividend Yield Return on Equity
HEINEKEN HOLDING (HEIO.AS) €82.85 2.11% 14.6%
HEINEKEN (HEIA.AS) €99.14 1.78% 14.6%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. HEINEKEN HOLDING (HEIO.AS)

2.11% Forward Dividend Yield and 14.6% Return On Equity

Heineken Holding N.V., through its subsidiaries, engages in brewing and selling of beer and cider. The company's portfolio consists of approximately 300 international, regional, local, and specialty beers and ciders. It operates in Africa, the Middle East, Europe, the Americas, and the Asia Pacific. The company was founded in 1864 and is based in Amsterdam, the Netherlands. Heineken Holding N.V. is a subsidiary of L'Arche Green N.V.

Earnings Per Share

As for profitability, HEINEKEN HOLDING has a trailing twelve months EPS of €-0.36.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.6%.

More news about HEINEKEN HOLDING.

2. HEINEKEN (HEIA.AS)

1.78% Forward Dividend Yield and 14.6% Return On Equity

Heineken N.V. brews and sells beer and cider in Europe, Americas, Africa, the Middle East, Eastern Europe, and the Asia Pacific. The company also provides soft drinks and water. It offers its beers under the Heineken, Amstel, Sol, Tiger, Birra Moretti, Pure Piraña, Desperados, Edelweiss, and Lagunitas brands; and cider under the Strongbow Apple Ciders, Orchard Thieves, Cidrerie Stassen, Bulmers, and Old Mout brands, as well as under regional and local brands. The company offers its products to retailers, wholesalers, cafes, bars, pubs, hotels, and restaurants. Heineken N.V. was founded in 1864 and is headquartered in Amsterdam, the Netherlands. Heineken N.V. is a subsidiary of Heineken Holding N.V.

Earnings Per Share

As for profitability, HEINEKEN has a trailing twelve months EPS of €-0.36.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.6%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Apr 24, 2023, the estimated forward annual dividend rate is 1.73 and the estimated forward annual dividend yield is 1.78%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HEINEKEN's stock is considered to be oversold (<=20).

Volume

Today's last reported volume for HEINEKEN is 86820 which is 84.83% below its average volume of 572665.

Revenue Growth

Year-on-year quarterly revenue growth grew by 27.7%, now sitting on 28.72B for the twelve trailing months.

More news about HEINEKEN.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com